<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[ohad hammer Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/ohad+hammer.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to ohad hammer]]></description>
	<s:counts start="0" returned="7" found="7" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Morphosys: A Biotech Rule Breaker (Part 1)]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F128452-morphosys-a-biotech-rule-breaker-part-1%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits:Morphosys (MPHSF.PK) is one of the most unusual biotech companies, as it breaks three basic rules that apply to drug development companies:  Rule No. 1: Development-stage companies burn cash and therefore must constantly raise capital and dilute existing shareholders. by Ohad Hammer]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 30 Mar 2009 04:02:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
	</item>
	<item>
		<title><![CDATA[Celgene Corporation: Take the Money and Run]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F123806-celgene-corporation-take-the-money-and-run%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: Of all the healthcare companies that took a beating in 2009, Celgene CELG seems to be the most undervalued one. Looking at the company&#8217;s financial performance and upside potential, it is very hard to understand how a growing biotech company with virtually no potential threat to its...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 03 Mar 2009 04:15:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Rigel and Seattle Genetics: The Delicate Art of Expectation Management]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F119415-rigel-and-seattle-genetics-the-delicate-art-of-expectation-management%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: In my previous article, I discussed the pharmaceutical industry&#8217;s race after approved drugs and late stage agents with proof of concept in humans. I mentioned Rigel&#8217;s RIGL lead drug, R788, as a likely target for collaboration due to its impressive activity, the huge addressable market and the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 09 Feb 2009 12:29:47 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/rigel+pharmaceuticals+inc..html"><![CDATA[Rigel Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seattle+genetics+inc..html"><![CDATA[Seattle Genetics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
		<category domain="tickers">RIGL,SGEN</category>
	</item>
	<item>
		<title><![CDATA[Rigel Still on Track, And Has Pfizer Found Its Next Blockbuster?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F113805-rigel-still-on-track-and-has-pfizer-found-its-next-blockbuster%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: In the pharmaceutical industry, 2008 will probably be marked by the big pharmas&#8217; insatiable appetite for new drugs. Threatened by fierce generic competition, the pharmaceutical giants were not only eager to pay generous acquisition premiums for marketed products, but were also willing to pay a lot of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 08 Jan 2009 03:16:44 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/rigel+pharmaceuticals+inc..html"><![CDATA[Rigel Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
		<category domain="tickers">PFE,RIGL</category>
	</item>
	<item>
		<title><![CDATA[Buying More Exelixis in the Post - GlaxoSmithKline Era]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F102271-buying-more-exelixis-in-the-post-glaxosmithkline-era%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: Only two and a half weeks have passed since the launch of the model portfolio, so it is still too early to assess its performance; nevertheless, even after a sharp decline in two stocks, the portfolio seems more robust than the general market. Since inception, the biotech...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 28 Oct 2008 02:23:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/portfolio.html"><![CDATA[Portfolio]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/exelixis+inc..html"><![CDATA[Exelixis Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EXEL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">EXEL,GSK</category>
	</item>
	<item>
		<title><![CDATA[Why It's Time to Buy More Immunogen]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F100391-why-it-s-time-to-buy-more-immunogen%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: Investing, particularly in biotech, comes with plenty of risks and uncertainties. These uncertainties are usually results of clinical trials, which are very unpredictable and unfortunately do not end up well in most cases.  Once in a while, a company and its stock price diverge in a way...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 17 Oct 2008 01:44:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/risk.html"><![CDATA[Risk]]></category>
		<category domain="http://resources.bnet.com/topic/stock+price.html"><![CDATA[Stock Price]]></category>
		<category domain="http://resources.bnet.com/topic/uncertainty.html"><![CDATA[Uncertainty]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/immunogen+inc..html"><![CDATA[ImmunoGen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
		<category domain="tickers">DNA,IMGN</category>
	</item>
	<item>
		<title><![CDATA[Genentech's Decision Should Boost Immunogen Stock]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F100025-genentech-s-decision-should-boost-immunogen-stock%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ohad Hammer submits: It finally happened. Yesterday, Genentech  DNA announced that they made a "go" decision to advance T-DM1  into a phase III trial. Although no official announcement is out as  of yet, Genentech's President of Product Development, Sue Hellmann,  left no doubt in her prepared...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 15 Oct 2008 07:53:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/product+development.html"><![CDATA[Product Development]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/product+marketing.html"><![CDATA[Product Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/ohad+hammer.html"><![CDATA[Ohad Hammer]]></category>
		<category domain="http://resources.bnet.com/topic/immunogen+inc..html"><![CDATA[ImmunoGen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
		<category domain="tickers">DNA,IMGN</category>
	</item>
</channel>
</rss>
